What role is there for antithymocyte globulin in allogeneic nonmyeloablative canine hematopoietic cell transplantation?

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 5, 2005, Pages 335-344

  Diaconescu, Razvan ^a   Little, Marie Térèse ^a   Leisenring, Wendy ^a,b   Yunusov, Murad ^a   Hogan, William J ^a   Sorror, Mohamed L ^a   Baron, Frédéric ^a   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antithymocyte globulin; Dog; Hematopoietic cell transplantation; Total body irradiation

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG RESPONSE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; MIXED LYMPHOCYTE REACTION; NONHUMAN; SKIN GRAFT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE SUBPOPULATION; WHOLE BODY RADIATION;

ANIMALS; ANTILYMPHOCYTE SERUM; BONE MARROW TRANSPLANTATION; DOGS; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; MODELS, ANIMAL; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 17444378263     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.01.001     Document Type: Article

References (33)

1. R. Storb C. Yu J.L. Wagner et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation Blood 89 1997 3048-3054
2. P.A. McSweeney D. Niederwieser J.A. Shizuru et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
3. M.B. Maris D. Niederwieser B.M. Sandmaier et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 102 2003 2021-2030
4. D. Niederwieser M. Maris J.A. Shizuru et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620-1629
5. R. Storb C. Yu T. Barnett et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation Blood 94 1999 1131-1136
6. W.J. Hogan M.-T. Little E. Zellmer et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates Biol Blood Marrow Transplant 9 2003 489-495
7. C.-Q. Xun M.-T. Little E. Zellmer et al. What role for FTY720, a novel immunosuppressive agent, in canine nonmyeloablative hematopoietic stem cell transplantation? Transplantation 73 2002 310-313
8. R. Storb C. Yu J.M. Zaucha et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant Blood 94 1999 2523-2529
9. L. Genestier S. Fournel M. Flacher O. Assossou J.P. Revillard N. Bonnefoy-Berard Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins Blood 91 1998 2360-2368
10. S. Slavin A. Nagler E. Naparstek et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
11. R. Storb R. Etzioni C. Anasetti et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia Blood 84 1994 941-949
12. R. Storb P.L. Weiden K.M. Sullivan et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: Use of a conditioning regimen including cyclophosphamide and antithymocyte globulin Blood 70 1987 116-121
13. T.R. Spitzer S. McAfee R. Sackstein et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies Biol Blood Marrow Transplant 6 2000 309-320
14. C. Grosskreutz V. Ross E. Scigliano S. Fruchtman L. Isola Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation Biol Blood Marrow Transplant 9 2003 453-459
15. J.L. Wagner R.C. Burnett S.A. DeRose L.V. Francisco R. Storb E.A. Ostrander Histocompatibility testing of dog families with highly polymorphic microsatellite markers Transplantation 62 1996 876-877
16. R.C. Burnett L.V. Francisco S.A. DeRose R. Storb E.A. Ostrander Identification and characterization of a highly polymorphic microsatellite marker within the canine MHC class I region Mamm Genome 6 1995 684-685
17. J.L. Wagner J.D. Works R. Storb DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing [brief communication] Tissue Antigens 52 1998 397-401
18. J.M. Zaucha E. Zellmer G. Georges et al. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required Biol Blood Marrow Transplant 7 2001 613-619
19. P.F. Moore P.V. Rossitto D.M. Danilenko J.J. Wielenga R.F. Raff E. Severns Monoclonal antibodies specific for canine CD4 and CD8 define functional T-lymphocyte subsets and high density expression of CD4 by canine neutrophils Tissue Antigens 40 1992 75-85
20. P.A. McSweeney K.A. Rouleau P.M. Wallace et al. Characterization of monoclonal antibodies that recognize canine CD34 Blood 91 1998 1977-1986
21. R.F. Raff H.J. Deeg V.T. Farewell S. DeRose R. Storb The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells Tissue Antigens 21 1983 360-373
22. X. Preville M. Flacher B. LeMauff et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model Transplantation 71 2001 460-468
23. H.D. Ochs R. Storb E.D. Thomas et al. Immunologic reactivity in canine marrow graft recipients J Immunol 113 1974 1039-1057
24. M.Y. Yunusov G.E. Georges R. Storb et al. FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease Transplantation 75 2003 933-940
25. n polymorphisms to determine the origin of blood cells after allogeneic canine marrow grafting Transplantation 58 1994 701-706
26. R. Storb R.F. Raff F.R. Appelbaum et al. What radiation dose for DLA-identical canine marrow grafts? Blood 72 1988 1300-1304
27. R. Storb R.F. Raff F.R. Appelbaum et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts Blood 74 1989 1139-1143
28. N.C. Gorin M. Labopin V. Rocha et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow Blood 102 2003 3043-3051
29. J. Sierra B. Storer J.A. Hansen et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: The effect of leukemic burden, donor HLA-matching, and marrow cell dose Blood 89 1997 4226-4235
30. J. Finke H. Bertz C. Schmoor et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin Br J Haematol 111 2000 303-313
31. M. Schleuning W. Gunther J. Tischer G. Ledderose H.J. Kolb Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML Bone Marrow Transplant 32 2003 243-250
32. E.K. Waller A.A. Langston S. Lonial et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation Biol Blood Marrow Transplant 9 2003 460-471
33. C. Wakabayashi T. Adachi J. Wienands T. Tsubata A distinct signaling pathway used by the IgG-containing B cell antigen receptor Science 298 2002 2392-2395